S&P 500   4,008.01 (-0.39%)
DOW   32,223.42 (+0.08%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
S&P 500   4,008.01 (-0.39%)
DOW   32,223.42 (+0.08%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
S&P 500   4,008.01 (-0.39%)
DOW   32,223.42 (+0.08%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
S&P 500   4,008.01 (-0.39%)
DOW   32,223.42 (+0.08%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
NASDAQ:SRNE

Sorrento Therapeutics (SRNE) Stock Forecast, Price & News

$1.44
+0.01 (+0.70%)
(As of 05/16/2022 04:00 PM ET)
Add
Compare
Today's Range
$1.39
$1.52
50-Day Range
$1.24
$2.62
52-Week Range
$1.15
$11.07
Volume
6.88 million shs
Average Volume
8.65 million shs
Market Capitalization
$560.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.43
30 days | 90 days | 365 days | Advanced Chart
Receive SRNE News and Ratings via Email

Sign-up to receive the latest news and ratings for Sorrento Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Sorrento Therapeutics logo

About Sorrento Therapeutics

Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 94 patients with COVID-19; Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California.

Headlines

Scilex, part of Sorrento Therapeutics names new CFO
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SRNE
Employees
799
Year Founded
N/A

Sales & Book Value

Annual Sales
$52.90 million
Book Value
$0.26 per share

Profitability

Net Income
$-428.33 million
Net Margins
-809.63%
Pretax Margin
-874.28%

Debt

Price-To-Earnings

Miscellaneous

Free Float
376,111,000
Market Cap
$560.08 million
Optionable
Optionable

Company Calendar

Today
5/16/2022
Next Earnings (Estimated)
5/18/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.83 out of 5 stars

Medical Sector

766th out of 1,423 stocks

Biological Products, Except Diagnostic Industry

117th out of 209 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -













Sorrento Therapeutics (NASDAQ:SRNE) Frequently Asked Questions

Is Sorrento Therapeutics a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sorrento Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Sorrento Therapeutics stock.
View analyst ratings for Sorrento Therapeutics
or view top-rated stocks.

When is Sorrento Therapeutics' next earnings date?

Sorrento Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, May 18th 2022.
View our earnings forecast for Sorrento Therapeutics
.

What price target have analysts set for SRNE?

1 analysts have issued twelve-month target prices for Sorrento Therapeutics' stock. Their forecasts range from $20.00 to $20.00. On average, they anticipate Sorrento Therapeutics' stock price to reach $20.00 in the next year. This suggests a possible upside of 1,288.9% from the stock's current price.
View analysts' price targets for Sorrento Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Sorrento Therapeutics' key executives?
Sorrento Therapeutics' management team includes the following people:
  • Dr. Henry H. Ji Ph.D., Chairman, Pres & CEO (Age 58, Pay $1.69M)
  • Mr. Brian Cooley, Sr. VP of Corp. Communications & Investor Relations
  • Mr. William J. Farley, VP of Sales & Bus. Devel. (Age 66)
  • Dr. Michael A. Royal, SVP & Chief Medical Officer (Age 68)
  • Dr. Alexis Nahama D.V.M., Sr. VP of Neurotherapeutics BU
  • Dr. Mark R. Brunswick, Sr. VP of Regulatory Affairs
  • Dr. Shawn Sahebi Ph.D., Sr. VP of Commercial Operations
  • Dr. Robert D. Allen Ph.D., Sr. VP of R&D
  • Dr. Xiao Xu M.D., Pres of ACEA
What other stocks do shareholders of Sorrento Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sorrento Therapeutics investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), Vaxart (VXRT), Advanced Micro Devices (AMD), Moderna (MRNA), NVIDIA (NVDA), ADMA Biologics (ADMA), Tesla (TSLA), Dynavax Technologies (DVAX) and NIO (NIO).

What is Sorrento Therapeutics' stock symbol?

Sorrento Therapeutics trades on the NASDAQ under the ticker symbol "SRNE."

Who are Sorrento Therapeutics' major shareholders?

Sorrento Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include State Street Corp (8.73%), BlackRock Inc. (5.67%), Vanguard Group Inc. (4.09%), JPMorgan Chase & Co. (0.85%), Northern Trust Corp (0.72%) and UBS Group AG (0.64%).
View institutional ownership trends for Sorrento Therapeutics
.

Which institutional investors are selling Sorrento Therapeutics stock?

SRNE stock was sold by a variety of institutional investors in the last quarter, including Citigroup Inc., JPMorgan Chase & Co., Mirae Asset Global Investments Co. Ltd., Northern Trust Corp, Group One Trading L.P., IMC Chicago LLC, swisspartners Ltd., and Metropolitan Life Insurance Co NY.
View insider buying and selling activity for Sorrento Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Sorrento Therapeutics stock?

SRNE stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, UBS Group AG, GSA Capital Partners LLP, Qube Research & Technologies Ltd, BlackRock Inc., Victory Capital Management Inc., Vanguard Group Inc., and IndexIQ Advisors LLC.
View insider buying and selling activity for Sorrento Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Sorrento Therapeutics?

Shares of SRNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sorrento Therapeutics' stock price today?

One share of SRNE stock can currently be purchased for approximately $1.44.

How much money does Sorrento Therapeutics make?

Sorrento Therapeutics has a market capitalization of $560.08 million and generates $52.90 million in revenue each year. The biopharmaceutical company earns $-428.33 million in net income (profit) each year or ($1.230010) on an earnings per share basis.

How many employees does Sorrento Therapeutics have?

Sorrento Therapeutics employs 799 workers across the globe.

What is Sorrento Therapeutics' official website?

The official website for Sorrento Therapeutics is www.sorrentotherapeutics.com.

How can I contact Sorrento Therapeutics?

Sorrento Therapeutics' mailing address is 4955 DIRECTORS PLACE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at (858) 203-4100, via email at [email protected], or via fax at 858-210-3759.

This page was last updated on 5/16/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.